

CHAPTER 3

REPORTABLE DISEASES, ARIZONA, 2008-2018

- 3A. NON-SEXUALLY TRANSMITTED DISEASES**
- 3B. SEXUALLY TRANSMITTED DISEASES**
- 3C. HUMAN IMMUNODEFICIENCY VIRUS (HIV)
DISEASE AND ACQUIRED IMMUNODEFICIENCY
SYNDROME (AIDS)**



3A.

NON-SEXUALLY TRANSMITTED DISEASES


The infectious diseases designated as notifiable vary slightly by state. A notifiable disease is one for which regular, frequent, and timely information regarding individual cases is considered necessary for the prevention and control of the disease. All states generally report the internationally quarantinable diseases (i.e., cholera or plague) in compliance with the World Health Organization's International Health Regulations.

Data on morbidity, levels of disease, and disability in the Arizona population are obtained for certain infectious diseases that must be reported by law. The Bureau of Epidemiology and Disease Control Services conducts surveillance and monitoring of these reportable diseases and it provided data for the respective sections of this chapter and sections 5F, 6A, and 6B.

This section provides some illustrative findings from the tabulated data. It is not intended to be an exhaustive analysis of the incidence of infectious diseases in the State. There is more information available online on the website of the Office of Infectious Disease Services at: <http://azdhs.gov/phs/oids/index.htm>.


3A. NON-SEXUALLY TRANSMITTED DISEASES

Figure 3A-1
Trends in the Incidence Rates^a of Valley Fever (Coccidioidomycosis)
by Year, Arizona, 2008-2018



Note: ^a Number of cases per 100,000 population.

Figure 3A-2
Trends in Case Fatality Rates^a for Valley Fever (Coccidioidomycosis)
by Year, Arizona, 2008-2018



Note: ^a Number of deaths per 100 reported cases.

Coccidioidomycosis or *Valley Fever* is a fungal infection caused by inhalation of airborne spores that are present in the soil of southwestern United States, California, and parts of Central and South America. Most infections are asymptomatic or self-limited in patients with healthy immune systems. In rare instances, severe lung disease or disseminated infection can develop in patients.

Valley Fever imposed the greatest burden on morbidity among all non-sexually transmitted, notifiable diseases in Arizona in 2018. The reported incidence of *Valley Fever* increased 8.6 percent from 2017 ($n=6,885$) to 2018 ($n=7,478$). The 2018 incidence rate of $105.7/100,000$ (Figure 3A-1, Table 5F-2) was 7.0 percent greater than the incidence rate of $98.8/100,000$ in 2017, but was 58.7 percent lower than the unprecedented incidence rate of $255.8/100,000$ in 2011.

Twenty six of the 7,478 Arizonans who had *Valley Fever* in 2018 died from it (Table 3A-2) for a case fatality rate of 0.3 deaths per 100 cases (Figure 3A-2). The 2018 case mortality rate for Coccidioidomycosis was 30.9 percent lower than in 2008.


3A. NON-SEXUALLY TRANSMITTED DISEASES

Shigellosis is an infectious disease caused by a group of bacteria called *Shigella* that can cause diarrhea in humans. To spread from one person to another, *Shigellae* can be transmitted through contaminated foods, sexual contact, and water used for drinking or recreational purposes.

From 2008–2018, *shigellosis* was the most common enteric disease to afflict Arizonans after *campylobacteriosis* and *salmonellosis* (**Table 3A-1**).

The number of reported cases of *shigellosis* has decreased by 77 cases from 555 in 2017 to 478 in 2018. Compared to 2017, The incidence rate of *shigellosis* was 15.0 percent lower at approximately 7 reported cases/100,000 population in 2018 (**Figure 3A-3**).

Figure 3A-3
Trends in the Incidence Rates^a of Shigellosis by Year,
Arizona, 2008-2018




Note: ^a Number of reported cases per 100,000 population.

Figure 3A-4
Trends in the Incidence Rates^a of Salmonellosis^b by Year,
Arizona, 2008-2018

Salmonellosis is a bacterial infection. Most of those who are infected with *Salmonella* develop diarrhea, fever, and abdominal cramps.


The incidence rate of *salmonellosis* increased 29.6 percent from 12.5/100,000 in 2017 to 16.2/100,000 in 2018 (**Figure 3A-4**). The risk of *salmonellosis* was substantially higher in Apache (53.2/100,000), Santa Cruz (42.0/100,000), Navajo (39.9/100,000) and Graham (39.3/100,000) than the remaining counties (**Table 5F-2**).



Notes: ^a Number of reported cases per 100,000 population; ^b Excluding S. Typhi and S. Paratyphi.


3A. NON-SEXUALLY TRANSMITTED DISEASES

Figure 3A-5
**Trends in the Incidence Rates^a of Hepatitis A by Year,
 Arizona, 2008-2018**



Note: ^a Number of reported cases per 100,000 population.

Figure 3A-6
Trends in the Incidence of Pulmonary Tuberculosis and Total Tuberculosis^a by Year, Arizona, 2008-2018



Note: ^a Number of reported cases by year.

Hepatitis A is a liver disease caused by the *hepatitis A* virus. During 1995-1996, highly effective *hepatitis A* vaccines became available in the United States. Routine childhood vaccination for *hepatitis A* was recommended in 1999. The expansion of recommendations for routine *hepatitis A* vaccination to include all children in the United States aged 12-23 months is likely to reduce hepatitis rates further.

In Arizona, the incidence rate of *hepatitis A* decreased 38.9 percent from 1.8/100,000 in 2008 to 1.1/100,000 in 2018 (**Figure 3A-5**).

Tuberculosis (TB) is an infectious disease that usually attacks the lungs, but can attack almost any part of the body. Tuberculosis is spread from person to person through the air.

The number of reported cases of *pulmonary tuberculosis* slightly decreased from 158 cases in 2017 to 155 reported cases in 2018. The number of reported cases of tuberculosis other than pulmonary decreased in 2018 to 23 cases (**Figure 3A-6, Table 3A-1**). The incidence rate of *total tuberculosis* decreased from 2.7/100,000 in 2017 to 2.5/100,000 in 2018 (**Table 5F-2**).

Pulmonary tuberculosis accounted for 87.1 percent of all tuberculosis infections in 2018 (**Table 3A-1**). Ten Arizonans who had *tuberculosis* died from it in 2018 (**Table 3A-2**).

TABLE 3A-1
NUMBER OF REPORTED CASES OF SELECTED NOTIFIABLE DISEASES BY CATEGORY, ARIZONA, 2008-2018

| Disease | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|-------|--------|--------|--------|--------|---------|-------|-------|-------|-------|-------|
| Vaccine Preventable | | | | | | | | | | | |
| Measles | 18 | 0 | * | * | * | * | * | 7 | 31 | 0 | 0 |
| Mumps | * | 10 | * | 0 | * | * | 12 | * | 7 | 34 | 15 |
| Pertussis | 218 | 277 | 546 | 867 | 1,130 | 1,440 | 517 | 580 | 287 | 420 | 239 |
| Pertussis confirmed cases | (23) | (79) | (95) | (160) | (575) | (1,068) | (287) | (341) | (154) | (262) | (135) |
| Rubella | * | 0 | * | 0 | 0 | 0 | 0 | 0 | 0 | * | 0 |
| Congenital Rubella Syndrome | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| <i>Haemophilus influenzae</i> type b (invasive, age < 5 years) | * | * | * | * | * | 0 | * | * | * | * | * |
| Tetanus | 0 | 0 | * | * | 0 | 0 | 0 | * | * | 0 | 0 |
| Varicella (chickenpox) | 778 | 534 | 755 | 660 | 535 | 354 | 300 | 270 | 279 | 189 | 245 |
| Central Nervous System | | | | | | | | | | | |
| Aseptic Meningitis | 688 | 516 | 733 | 400 | 453 | 343 | 288 | 189 | 146 | 81 | N/A |
| Meningococcal Disease | 9 | 15 | 14 | 16 | 6 | 12 | 9 | * | * | * | * |
| Viral Encephalitis | 8 | * | 6 | 6 | * | * | * | * | * | * | * |
| Enteritides | | | | | | | | | | | |
| Amebiasis | 11 | 7 | 13 | 21 | 17 | 21 | 24 | * | 6 | 16 | 21 |
| Campylobacteriosis | 1,006 | 877 | 956 | 939 | 940 | 846 | 939 | 1,379 | 1,241 | 1,372 | 1,269 |
| Cholera | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | * |
| Cryptosporidiosis | 89 | 34 | 40 | 46 | 47 | 42 | 46 | 62 | 549 | 112 | 203 |
| <i>E. coli</i> O157:H7 | 69 | 68 | 100 | 126 | 141 | 246 | 98 | 128 | 148 | 166 | 296 |
| Giardiasis | 142 | 198 | 167 | 133 | 113 | 115 | 119 | 143 | 125 | 145 | 149 |
| Salmonellosis (ex. <i>S. Typhi</i> & <i>S. Paratyphi</i>) | 1,143 | 1,079 | 984 | 877 | 857 | 1,007 | 1,040 | 1,143 | 899 | 874 | 1,149 |
| <i>Salmonella</i> Paratyphi A | * | * | 7 | * | 0 | * | * | * | * | * | * |
| <i>Salmonella</i> Paratyphi B | 10 | 6 | * | 7 | * | * | * | 16 | 0 | 0 | 0 |
| <i>Salmonella</i> Paratyphi C | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shigellosis | 650 | 806 | 465 | 434 | 444 | 428 | 376 | 549 | 1,231 | 555 | 478 |
| Typhoid Fever | * | * | 6 | * | 7 | 12 | * | * | 9 | * | 9 |
| Mycosis | | | | | | | | | | | |
| Coccidioidomycosis (Valley Fever) | 4,768 | 10,233 | 11,888 | 16,472 | 12,920 | 5,861 | 5,624 | 7,622 | 6,101 | 6,885 | 7,478 |
| Hepatitis | | | | | | | | | | | |
| Hepatitis A | 118 | 68 | 62 | 77 | 93 | 73 | 35 | 72 | 46 | 61 | 80 |
| Hepatitis B (acute) | 163 | 193 | 150 | 185 | 104 | 50 | 38 | 43 | 16 | 41 | 30 |
| Hepatitis C (acute) | 0 | 0 | 0 | NA | NA | NA | NA | NA | NA | NA | N/A |
| Hepatitis D | 0 | 0 | * | 0 | 0 | * | 0 | 0 | 0 | 0 | * |
| Hepatitis E | 0 | 0 | * | 0 | 0 | * | 0 | 0 | * | 0 | 0 |
| Tuberculosis | | | | | | | | | | | |
| Pulmonary TB | 179 | 188 | 229 | 209 | 186 | 168 | 162 | 167 | 153 | 158 | 155 |
| Total TB | 227 | 232 | 282 | 255 | 211 | 184 | 193 | 198 | 188 | 188 | 178 |

TABLE 3A-1 (continued)
NUMBER OF REPORTED CASES OF SELECTED NOTIFIABLE DISEASES BY CATEGORY, ARIZONA, 2008-2018

| Disease | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|
| Zoonoses/Vector-borne | | | | | | | | | | | |
| Brucellosis | * | * | 9 | * | * | * | 6 | * | * | 8 | * |
| Colorado Tick Fever | 0 | 0 | * | 0 | 0 | * | * | * | 0 | 0 | * |
| Dengue | 6 | * | 10 | * | 10 | * | 91 | 24 | 14 | * | 10 |
| Erlichiosis | * | * | 0 | * | * | * | * | * | * | * | * |
| Hantavirus Pulmonary Syndrome | * | * | 0 | * | * | * | * | * | * | * | 0 |
| Human Rabies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Lyme Disease | 8 | 7 | * | 15 | 13 | 32 | 21 | 12 | 13 | 28 | 7 |
| Malaria | 17 | 10 | 28 | 21 | 19 | 33 | 25 | 14 | 38 | 26 | 24 |
| Plague | * | 0 | 0 | 0 | 0 | 0 | 0 | * | 0 | * | 0 |
| Relapsing Fever, Tick-borne | 0 | * | 0 | * | * | * | 12 | * | * | * | * |
| Rocky Mountain Spotted Fever | 17 | 23 | 17 | 77 | 50 | 63 | 16 | 17 | 23 | 27 | 38 |
| St. Louis Encephalitis | 0 | 0 | 0 | 0 | 0 | * | * | 23 | 0 | 6 | 0 |
| Tularemia | 0 | 0 | * | 0 | 0 | 0 | * | * | * | * | 0 |
| West Nile Virus | 114 | 21 | 166 | 69 | 135 | 62 | 108 | 103 | 78 | 110 | 27 |
| Other | | | | | | | | | | | |
| Botulism | * | * | 0 | * | 12 | * | * | * | * | * | 12 |
| Legionellosis | 26 | 49 | 65 | 46 | 44 | 69 | 59 | 93 | 76 | 74 | 83 |
| Listeriosis | 8 | 8 | 10 | 8 | 14 | * | 14 | * | 6 | 8 | 6 |
| Methicillin Resistant <i>S. aureus</i> (invasive) | 1,417 | 1,171 | 1,166 | 1,196 | 1,089 | 1,066 | 1,178 | 1,155 | 1,265 | 1,355 | 1,529 |
| Streptococcal-Group A (invasive) | 204 | 161 | 190 | 206 | 199 | 231 | 250 | 351 | 555 | 614 | 758 |
| Streptococcal-Group B (invasive, age <90 d) | 57 | 52 | 45 | 39 | 57 | 35 | 41 | 61 | 60 | 63 | 40 |
| Streptococcus pneumoniae (invasive) | 1,077 | 907 | 823 | 767 | 661 | 786 | 724 | 678 | 716 | 707 | 862 |
| Reyes Syndrome | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Toxic Shock Syndrome | * | * | * | * | * | * | 6 | * | * | 0 | * |
| <i>Vibrio</i> spp. (except toxigenic <i>V cholerae</i>) | 14 | 19 | 18 | 26 | 29 | 19 | 36 | 33 | 19 | 25 | 54 |
| Yersiniosis (except <i>Y. pestis</i>) | * | 7 | * | 6 | 10 | 9 | * | 12 | 14 | 20 | 11 |

Notes: * Cell suppressed due to non-zero count less than 6; Non-resident cases have been excluded. Only incident cases are reported. Cases are counted by date reported to public health. Case counts include both probable and confirmed cases unless otherwise indicated. *E. coli* O157:H7 and Shiga-toxin positive *E. coli* since October 2004.

Haemophilus influenzae type B includes all invasive *H. influenzae* B, not just meningitis, as of 1995. Meningococcal disease includes all invasive disease caused by *Neisseria meningitidis*, not just meningitis. Animal rabies cases are not included. Reported coccidioidomycosis cases were elevated from June 2009 through December 2012 and then declined in 2013 due to changes in reporting practices and laboratory testing from a major commercial laboratory. A change in the criteria for counting Lyme disease in 2013 may account for the increase in cases in that year. Aseptic meningitis and Reyes syndrome ceased being reportable in January 2018. For additional statistics on these diseases, please see:

<https://azdhs.gov/preparedness/epidemiology-disease-control/index.php#data-stats>

Source: Arizona Department of Health Services, Bureau of Epidemiology and Disease Control Services and Office of Disease Integration and Services.

TABLE 3A-2
NUMBER OF DEATHS FROM SELECTED NOTIFIABLE DISEASES BY CATEGORY AND YEAR,
ARIZONA, 2008-2018

| ICD-9/ICD-10 codes | Disease | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--------------------------------|-----------------------------------|------|------|------|------|------|------|------|------|------|------|------|
| VACCINE PREVENTABLE | | | | | | | | | | | | |
| 055/B05 | Measles | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 072/B26 | Mumps | 0 | 0 | 0 | 0 | 0 | 0 | 0 | * | 0 | 0 | 0 |
| 033/A37 | Whooping cough (pertussis) | * | * | 0 | 0 | 0 | 0 | 0 | 0 | * | * | 0 |
| 056/B06 | Rubella | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 052/B01 | Chickenpox | 0 | * | * | * | * | 0 | * | 0 | 0 | 0 | * |
| CENTRAL NERVOUS SYSTEM | | | | | | | | | | | | |
| 047.9/G03.0 | Aseptic meningitis | * | * | 0 | * | * | 0 | 0 | * | 0 | * | * |
| 036/A39 | Meningococcal infections | 0 | 0 | * | * | * | * | * | 0 | 0 | 0 | 0 |
| 049.9/A86 | Viral encephalitis | * | * | * | 6 | * | * | * | * | * | * | * |
| ENTERITIDES (FOODBORNE) | | | | | | | | | | | | |
| 006/A06 | Amebiasis | 0 | 0 | 0 | 0 | 0 | 0 | * | 0 | 0 | 0 | 0 |
| 007.1/A07.1 | Giardiasis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 003/A02 | Salmonellosis (except typhoid) | * | 0 | * | * | 0 | 0 | * | * | * | * | * |
| 004/A03 | Shigellosis | 0 | * | * | 0 | 0 | * | * | * | 0 | 0 | 0 |
| 002/A01 | Typhoid | * | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| MYCOSIS | | | | | | | | | | | | |
| 114/B38 | Coccidioidomycosis (Valley Fever) | 24 | 35 | 39 | 22 | 25 | 19 | 25 | 28 | 28 | 28 | 26 |
| HEPATITIDES | | | | | | | | | | | | |
| 070.0-070.1/B15 | Hepatitis A | * | * | * | 0 | * | * | * | 0 | 0 | 0 | 0 |
| 070.2-070.3/B16 | Hepatitis B | 6 | * | 10 | 9 | 12 | 9 | 8 | 8 | 10 | * | 6 |
| 070.4-070.5/B17-B18 | Other viral hepatitis | 176 | 233 | 207 | 209 | 274 | 265 | 248 | 257 | 207 | 191 | 133 |
| 070.6-070.9/B19 | Unspecified | * | * | * | 0 | 0 | * | * | * | 0 | * | * |
| TUBERCULOSIS | | | | | | | | | | | | |
| 010-011/A15-A16 | Respiratory TB | 10 | 8 | 12 | 10 | * | 11 | 6 | 9 | 6 | 7 | * |
| 010-018/A15-A19 | Total TB | 13 | 8 | 15 | 12 | * | 15 | 8 | 10 | 7 | 10 | 10 |
| ZOONOSES/VECTOR-BORNE | | | | | | | | | | | | |
| 023.9/A23 | Brucellosis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | * | 0 | 0 | 0 |
| 061/A90 | Dengue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 071/A82 | Human Rabies | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 084/B50-B54 | Malaria | 0 | 0 | 0 | 0 | 0 | * | 0 | 0 | 0 | 0 | 0 |
| 020/A20 | Plague | 0 | 0 | 0 | 0 | * | 0 | 0 | 0 | 0 | 0 | 0 |
| 082/A77.0 | Rocky Mountain Spotted Fever | * | * | * | * | 0 | * | 0 | 0 | * | * | 0 |
| 021/A21 | Tularemia | 0 | 0 | 0 | 0 | 0 | 0 | * | 0 | 0 | 0 | 0 |
| OTHER | | | | | | | | | | | | |
| 482.8/A48.1 | Legionellosis | 0 | * | 0 | * | * | * | * | * | * | 0 | 6 |
| 027.0/A32 | Listeriosis | 0 | 0 | 0 | 0 | * | 0 | * | 0 | 0 | 0 | 0 |
| 331.8/G93.7 | Reyes Syndrome | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 995.0/A48.3 | Toxic Shock Syndrome | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | * | 0 | 0 |

Note: * Cell suppressed due to non-zero count less than 6.



3B.

SEXUALLY TRANSMITTED DISEASES


All states require that certain sexually transmitted diseases (STDs) be reported by physicians and other health care providers when they suspect that a case has occurred or they have laboratory confirmation.

It is important to note that disease reporting is likely incomplete and completeness may vary depending on the disease. Moreover, changes in methods for public health surveillance, or implementation of new diagnostic tests can cause changes in disease reporting that are independent of the true incidence of disease.* In this section, STD rates were calculated using denominators from the CDC for years prior 2018. In the current report, the Arizona Department of Health Services denominators were used to compute the STD rates.

*Centers for Disease Control and Prevention. Summary of notifiable diseases – United States, 2008. Published June 25, 2010, for 2008; Vol. 57 (No. 54). Available online at <http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5754a1.htm>


3B. SEXUALLY TRANSMITTED DISEASES

Figure 3B-1
Trends in the Incidence Rates^a of Gonorrhea by Year, Arizona, 2008-2018



Note: ^a Number of reported cases per 100,000 population.

Figure 3B-2
Trends in the Incidence Rates^a of Gonorrhea among Females aged 15-24 and 15-44 Years, Arizona, 2008-2018



Notes: ^a Number of reported cases per 100,000 females; There was a change in target rate and age range for Healthy People 2020 objective. In National Year 2010 objective was for females aged 15 and 24 years. In Healthy People 2020 objective is for females aged 15 and 44 years.

Neisseria gonorrhoeae infection is the second most commonly reported notifiable disease in the United States. (**Figure 3B-1**). The consistent steady increase in the incidence rate of gonorrhea since 2009 likely resulted from a combination of factors, such as changes in surveillance, increases in the number of tests performed, and actual increases in disease occurrence (**Figure 3B-1**).

The *Healthy People* 2010 objective HP25-2 defines the target rate for gonorrhea as equal to or lower than 19.1 cases per 100,000 population. However, the *Healthy People* 2020 target is for ages 15-44 and is set at 151.0/100,000 females and 147.0/100,000 males (**Table 6A-2**).

The 2018 incidence rate for gonorrhea was 372.8 per 100,000 for Arizona females aged 15-44 years, meaning Arizona's incidence rate was higher than the *Healthy People* 2020 objective. Generally, the trends in gonorrhea incidence rates are similar for women in the age groups 15-24 and 15-44, although the overall incidence rate is consistently higher for women aged 15-24.

3B. SEXUALLY TRANSMITTED DISEASES

Chlamydia trachomatis is the most prevalent bacterial sexually transmitted disease in the United States (1,758,668 cases in 2018) with the highest rates reported among adolescents and young adults (**Table 3B-4**). Recent availability of sensitive tests for chlamydia using DNA amplification technology undoubtedly contributed to the increase in the number of reported cases in Arizona over the last decade (**Figure 3B-3, Table 3B-1**).

The incident rate of chlamydia was previously reported for females aged 15-24 years, however based on changes in *Healthy People 2020*, it would be reported for females 15-44 years. The *Healthy People 2020* goal for chlamydia is set at 1,478.2 per 100,000 females. The incidence rate for Arizona in 2018 was 1,958 per 100,000 females age 15-44 years (**Table 6A-2**).


<http://www.cdc.gov/std/stats18/chlamydia.htm>

Congenital syphilis is an infection caused by the spirochete *Treponema pallidum*, which can be passed from the mother to child during fetal development or birth. Not all infants born to infected women will be infected.

In 1988, CDC implemented a new Congenital syphilis case definition. It no longer relies on documentation of infection in the infant; rather, it presumes that an infant is infected if it cannot be proven that an infected mother was adequately treated for syphilis before or during pregnancy.

The *Healthy People 2020* goal for congenital syphilis is 14.5 cases per 100,000, which has been surpassed by Arizona in each year from 2008 to 2018, with sole exception of 2014. The Arizona incidence rates of congenital syphilis were for the most part below 20 cases per 100,000 infants, with exception to years prior 2010 and after 2016. In 2017, a sharp increase in the incidence was recorded (36.7/100,000), and in 2018, the rate more than doubled at 75.7/100,000 (**Figure 3B-4, Table 6A-2**).

Figure 3B-3
Trends in the Incidence Rates^a of Chlamydia among Females 15-24 and 15-44 Years, Arizona, 2008-2018



Notes: ^a Number of reported cases per 100,000 females; There was a change in target rate and age range for Healthy People 2020 objective. In National Year 2010 objective was for females aged 15-24 years. In Healthy People 2020 objective is for females aged 15-44 years.

Figure 3B-4
Trends in the Incidence Rates^a of Congenital Syphilis by Year, Arizona, 2008-2018




TABLE 3B-1
NUMBER OF REPORTED CASES OF SEXUALLY TRANSMITTED DISEASES BY CATEGORY AND YEAR, ARIZONA, 2008-2018

| Disease | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| Gonorrhea | 3,449 | 3,250 | 3,249 | 4,564 | 5,856 | 6,505 | 7,585 | 8,270 | 10,330 | 12,514 | 12,903 |
| Gonococcal PID^a | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | * | 17 |
| Resistant Gonorrhea^b | 0 | 0 | 0 | 0 | 0 | 0 | * | 0 | 0 | 0 | 0 |
| Syphilis (P & S)^c | 317 | 231 | 230 | 274 | 204 | 290 | 572 | 590 | 721 | 943 | 1,052 |
| Syphilis-Total^d | 1,396 | 1,085 | 904 | 907 | 795 | 966 | 1,434 | 1,482 | 1,903 | 2,424 | 3,258 |
| Chlamydia | 24,769 | 26,002 | 26,861 | 29,251 | 30,571 | 30,923 | 31,750 | 32,511 | 34,923 | 39,635 | 40,866 |

Notes: * Cell suppressed due to non-zero count less than 6; ^a PID is pelvic inflammatory disease; ^b Includes PPNG, penicillase producing Neisseria gonorrhoea, a form of gonorrhea which is resistant to penicillin; ^c Primary and secondary syphilis only; ^d Early, late, congenital and other; since 2005, the table includes all positive laboratory results for chlamydia and gonorrhea with or without communicable disease report.

Source: Arizona Department of Health Services, Bureau of Epidemiology and Disease Control, Office of HIV / STD.

TABLE 3B-2
**NUMBER OF DEATHS ASSOCIATED WITH SPECIFIED SEXUALLY TRANSMITTED DISEASES BY CATEGORY AND YEAR,
ARIZONA, 2008-2018**

| Disease | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|------------------------------|------|------|------|------|------|------|------|------|------|------|------|
| Gonococcal infections | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Syphilis-Total | * | 0 | 0 | * | * | * | * | 0 | * | * | * |

Notes: * Cell suppressed due to non-zero count less than 6; Number of deaths associated with Syphilis are still birth (congenital syphilis).

TABLE 3B-3
FREQUENCY OF REPORTED CASES OF GONORRHEA, CHLAMYDIA, AND EARLY SYPHILIS
BY AGE AND GENDER, ARIZONA, 2018

| Age group | GONORRHEA | | | | CHLAMYDIA | | | | EARLY SYPHILIS | | | |
|----------------|-----------|---------|------------------------|---------|-----------|---------|------------------------|---------|----------------|---------|------------------------|--------|
| | Males | Females | Unknown or Transgender | Total | Males | Females | Unknown or Transgender | Total | Males | Females | Unknown or Transgender | Total |
| 0-4 | * | * | 0 | 10† | * | * | 0 | 10† | 0 | 0 | 0 | 0 |
| 5-9 | 0 | * | 0 | 0† | * | * | 0 | 10† | 0 | 0 | 0 | 0 |
| 10-14 | * | 32 | 0 | 40† | 46 | 164 | 0 | 210 | * | 0 | 0 | 0† |
| 15-19 | 724 | 937 | * | 1,664 | 2,312 | 7,050 | 30 | 9,392 | 57 | 39 | 0 | 96 |
| 20-24 | 1,838 | 1,509 | 6 | 3,353 | 4,661 | 10,185 | 34 | 14,880 | 223 | 91 | 0 | 314 |
| 25-29 | 1,724 | 1,121 | * | 2,849 | 3,038 | 4,928 | 27 | 7,993 | 294 | 89 | 0 | 383 |
| 30-34 | 1,170 | 782 | 6 | 1,958 | 1,628 | 2,183 | 12 | 3,823 | 244 | 72 | 0 | 316 |
| 35-39 | 742 | 474 | * | 1,220 | 1,008 | 1,113 | 6 | 2,127 | 213 | 52 | 0 | 265 |
| 40-44 | 446 | 233 | * | 681 | 538 | 593 | * | 1,135 | 139 | 28 | 0 | 167 |
| 45-49 | 359 | 138 | * | 498 | 339 | 258 | * | 598 | 126 | 21 | 0 | 147 |
| 50-54 | 248 | 69 | * | 318 | 208 | 125 | 0 | 333 | 113 | 8 | 0 | 121 |
| 55-59 | 152 | 25 | * | 179 | 131 | 76 | * | 209 | 71 | 7 | 0 | 78 |
| 60-64 | 55 | 12 | 0 | 67 | 46 | 35 | * | 82 | 37 | * | 0 | 40† |
| 65-over | 62 | 7 | 0 | 69 | 44 | 24 | 0 | 68 | 21 | * | 0 | 20† |
| Total | 7,530† | 5,340† | 30† | 12,900† | 14,000† | 26,740† | 120† | 40,860† | 1,540† | 410† | 0 | 1,950† |

Notes: * Cell suppressed due to non-zero count less than 6; † Sum rounded to nearest tens unit due to non-zero addend less than 6; since 2005, the table includes all positive laboratory results for chlamydia and gonorrhea with or without communicable disease report; In 2018, 3 gonorrhea and 4 chlamydia cases were excluded due to missing age.

Source: Arizona Department of Health Services, Bureau of Epidemiology and Disease Control Services, Office of HIV / STD.

TABLE 3B-4
RATES^a OF REPORTED CASES OF GONORRHEA, CHLAMYDIA, AND EARLY SYPHILIS
BY AGE AND GENDER, ARIZONA, 2018

| Age group | GONORRHEA | | | CHLAMYDIA | | | EARLY SYPHILIS | | |
|----------------|-----------|---------|-------|-----------|---------|--------|----------------|---------|-------|
| | Males | Females | Total | Males | Females | Total | Males | Females | Total |
| 0-4 | ** | ** | ** | ** | ** | 1.6 | 0.0 | 0.0 | 0.0 |
| 5-9 | 0.0 | ** | ** | ** | ** | 0.0 | 0.0 | 0.0 | 0.0 |
| 10-14 | ** | 13.9 | 7.9 | 19.2 | 71.2 | 44.7 | ** | 0.0 | ** |
| 15-19 | 300.3 | 406.8 | 353.0 | 959.1 | 3060.8 | 1992.4 | 23.7 | 16.9 | 20.4 |
| 20-24 | 721.0 | 645.2 | 685.9 | 1828.3 | 4354.4 | 3044.0 | 87.5 | 38.9 | 64.2 |
| 25-29 | 658.9 | 463.0 | 565.5 | 1161.1 | 2035.3 | 1586.6 | 112.4 | 36.8 | 76.0 |
| 30-34 | 492.5 | 352.5 | 426.2 | 685.3 | 984.0 | 832.2 | 102.7 | 32.5 | 68.8 |
| 35-39 | 325.5 | 215.2 | 272.2 | 442.1 | 505.4 | 474.6 | 93.4 | 23.6 | 59.1 |
| 40-44 | 213.3 | 112.2 | 163.4 | 257.2 | 285.6 | 272.3 | 66.5 | 13.5 | 40.1 |
| 45-49 | 167.2 | 63.9 | 115.6 | 157.9 | 119.4 | 138.8 | 58.7 | 9.7 | 34.1 |
| 50-54 | 118.9 | 32.1 | 75.1 | 99.8 | 58.2 | 78.7 | 54.2 | 3.7 | 28.6 |
| 55-59 | 71.7 | 11.0 | 40.8 | 61.8 | 33.4 | 47.6 | 33.5 | 3.1 | 17.8 |
| 60-64 | 28.3 | 5.5 | 16.2 | 23.7 | 15.9 | 19.8 | 19.0 | ** | 9.7 |
| 65-over | 11.1 | 1.1 | 5.7 | 7.9 | 3.7 | 5.6 | 3.8 | ** | 1.9 |
| Total | 213.9 | 150.2 | 182.3 | 398.0 | 751.7 | 577.5 | 43.7 | 11.6 | 27.6 |

Notes: ** Cell suppressed due to rate/ratio/percent based on non-zero count less than 6; ^a Number of cases per 100,000 population; table includes all positive laboratory results for chlamydia and gonorrhea with or without communicable disease report in 2017; denominators for unknown or transgender category are not available; rates per 100,000 population.

Source: Arizona Department of Health Services, Bureau of Epidemiology and Disease Control Services, Office of HIV / STD.

TABLE 3B-5
**FREQUENCY OF REPORTED CASES, PERCENT DISTRIBUTION AND RATES OF EARLY AND LATE SYPHILIS,
 GONORRHEA, AND CHLAMYDIA BY RACE/ETHNICITY, ARIZONA, 2018**

| Race/ethnicity | SYPHILIS | | | GONORRHEA | | | CHLAMYDIA | | |
|---|-------------|--------|------------|-------------|-------|--------|-------------|-------|--------|
| | Early Cases | Rate % | Late Cases | Resistant % | Cases | Rate % | Total Cases | % | Rate |
| White Non-Hispanic | 686 | 35.2 | 17.4 | 322 | 25.9 | 8.2 | 0 | 0.0 | 0.0 |
| Black or African American | 199 | 10.2 | 58.5 | 141 | 11.3 | 41.5 | 0 | 0.0 | 2,152 |
| Hispanic or Latino | 729 | 37.4 | 32.7 | 523 | 42.0 | 23.5 | 0 | 0.0 | 3,408 |
| Asian or Pacific Islander | 33 | 1.7 | 12.6 | 14 | 1.1 | 5.3 | 0 | 0.0 | 123 |
| American Indian or Alaska Native | 234 | 12.0 | 78.3 | 141 | 11.3 | 47.2 | 0 | 0.0 | 1,157 |
| Multi-racial | 45 | 2.3 | N/A | 21 | 1.7 | N/A | 0 | 0.0 | 150 |
| Not Specified | 25 | 1.3 | N/A | 83 | 6.7 | N/A | 0 | 0.0 | 2,684 |
| Total | 1,951 | 100.0 | 27.6 | 1,245 | 100.0 | 17.6 | 0 | N/A | 12,903 |
| | | | | | | | 100.0 | 182.3 | 40,866 |
| | | | | | | | | 100.0 | 577.5 |

Notes: ^a Number of cases per 100,000 population; Table includes all positive laboratory results for chlamydia and gonorrhea with or without communicable disease report in 2018; rates per 100,000 population.

Source: Arizona Department of Health Services, Bureau of Epidemiology and Disease Control Services, Office of HIV / STD.




3C.

HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE AND ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

Statistics about the estimated incidence of Human Immunodeficiency Virus (HIV) disease and Acquired Immunodeficiency Syndrome (AIDS) for 1981-2018, as provided by the Office of HIV, STD, and Hepatitis Services, are available in Tables 3C-1, 3C-2, 3C-3, 3C-4, and 5F-3 of this report. In the past, the cases of persons previously reported as HIV positive and subsequently diagnosed with AIDS were not properly counted since these were not new cases, only a new diagnosis reflecting a progression of the disease. The data presented in this report are based on a revised approach adopted by the Office of HIV/AIDS Services. The estimated incidence of HIV/AIDS includes the sum of new HIV cases and new AIDS cases, which were not diagnosed as HIV positive in any prior calendar year. The cases of persons who were diagnosed with both HIV and AIDS in the same calendar year are counted only as AIDS to avoid double counting.

3C. HIV DISEASE AND AIDS

Figure 3C-1
**Reported Cases of HIV/AIDS by Gender and Year of Diagnosis,
Arizona, 2008-2018**




Since the first case of AIDS diagnosed in an Arizona resident in 1981, a total of 24,468 cases of HIV/AIDS had been diagnosed in the State by the end of 2018 and reported by July 1, 2019 (**Table 3C-1**).

In 2018, males accounted for 87.7 percent of all HIV/AIDS diagnoses. The male-to-female ratio of HIV/AIDS diagnoses in Arizona in 2018 was 7.1:1 (726/102; **Figure 3C-1, Table 3C-2**).

The proportion of risk behaviors attributed to emerging cases of HIV/AIDS in 2018 remained similar to previous years. Of the 828 HIV/AIDS cases diagnosed in 2018, 527 were among men who reported sexual contact with other men (**Table 3C-4**). Another 51 reported heterosexual contact. An additional 48 reported only injecting drugs. Adults without an indicated risk accounted for 160 of HIV/AIDS cases diagnosed in 2018.

Figure 3C-2
**Trends in the Incidence Rates of HIV/AIDS and Mortality Rates for HIV Disease
by Year, Arizona, 2008-2018**



The incidence rate measures the relative risk for HIV/AIDS in a population. The incidence rate of HIV/AIDS has increased in Arizona by 9.3 percent from 10.7 cases per 100,000 population in 2008 to 11.7/100,000 in 2018 (**Figure 3C-2**; the incidence rates for 2008 - 2018 have been re-computed based on the latest volume of the HIV/AIDS data as of 7/01/2019).

The rate of deaths from HIV disease remained unchanged from 2014 to 2015, then decreased slightly at 1.4 deaths per 100,000 population in 2016 to 1.1 in 2018 (**Figure 3C-2**).

Of the 828 HIV/AIDS cases diagnosed in 2018, 281 were White non-Hispanic, 331 were Hispanic, 145 were Black, 44 were American Indian, and 20 were Asian or Pacific Islander (**Table 3C-3**).

Notes: *By year of diagnosis; **By year of death.

TABLE 3C-1
FREQUENCY DISTRIBUTION OF HIV/AIDS BY AGE AT DIAGNOSIS,
ARIZONA, 1981-2018

| Age Group (years) | HIV/AIDS cases |
|----------------------|----------------|
| Under 5 | 130 |
| 5-12 | 62 |
| 13-19 | 565 |
| 20-29 | 7,378 |
| 30-39 | 8,637 |
| 40-49 | 5,050 |
| 50 or above | 2,628 |
| Missing | 18 |
| Total | 24,468 |

TABLE 3C-2
HIV/AIDS CASES AND DEATHS BY YEAR OF DIAGNOSIS AND GENDER,
ARIZONA, 1981-2007 and 2008-2018

| | 1981-2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--------------------------|------------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| # Males | 14,771 | 613 | 573 | 553 | 489 | 536 | 611 | 636 | 613 | 630 | 629 | 726 |
| # Females | 2,055 | 83 | 85 | 76 | 78 | 92 | 90 | 114 | 101 | 105 | 107 | 102 |
| # Total | 16,826 | 696 | 658 | 629 | 567 | 628 | 701 | 750 | 714 | 735 | 736 | 828 |
| # Presumed Living | 8,971 | 594 | 560 | 552 | 507 | 563 | 645 | 707 | 665 | 700 | 708 | 813 |
| # Known dead | 7,855 | 102 | 98 | 77 | 60 | 65 | 56 | 43 | 49 | 35 | 28 | 15 |
| % Mortality | 47.4 | 13.6 | 13.8 | 10.7 | 9.2 | 8.9 | 6.7 | 4.7 | 5.7 | 3.9 | 3.3 | 1.8 |

Note: Due to reporting delays, all numbers are provisional (2018 volume as of 07/01/2019).

Source: Arizona Department of Health Services, Bureau of Epidemiology and Disease Control, Office of HIV/AIDS Services.

TABLE 3C-3
**DISTRIBUTION OF REPORTED HIV/AIDS CASES BY YEAR OF DIAGNOSIS AND RACE/ETHNICITY,
ARIZONA, 1981-2007 AND 2008-2018**

| Race/ethnicity | 1981-2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|--|-----------|------|------|------|------|------|------|------|------|------|------|------|
| White non-Hispanic | 10,339 | 342 | 282 | 312 | 227 | 245 | 284 | 270 | 249 | 248 | 251 | 281 |
| Black or African American non-Hispanic | 1,625 | 71 | 69 | 59 | 76 | 103 | 116 | 132 | 132 | 137 | 116 | 145 |
| Hispanic or Latino all races | 3,942 | 231 | 245 | 203 | 211 | 242 | 268 | 251 | 274 | 297 | 331 | |
| Asian or Pacific Islander non-Hispanic | 113 | 15 | 13 | 10 | 16 | 16 | 9 | 17 | 23 | 17 | 23 | 20 |
| American Indian or Alaska Native non-Hispanic | 533 | 28 | 39 | 36 | 41 | 45 | 46 | 58 | 52 | 54 | 46 | 44 |
| Two or more races / other or unknown race | 274 | 9 | 10 | 9 | * | 8 | * | * | 7 | * | * | 7 |
| Total | 16,826 | 696 | 658 | 629 | 570† | 628 | 700† | 750† | 714 | 740† | 740† | 828 |

Note: * Cell suppressed due to non-zero count less than 6; † Sum rounded to nearest tens unit due to non-zero addend less than 6; Due to reporting delays, all numbers are provisional (2018 volume as of 07/01/2019).

TABLE 3C-4
**DISTRIBUTION OF REPORTED HIV/AIDS CASES BY YEAR OF DIAGNOSIS AND TRANSMISSION CATEGORY,
ARIZONA, 1981-2007 AND 2008-2018**

| Transmission | 1981-2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 |
|---|-----------|------|------|------|------|------|------|------|------|------|------|------|
| MSM | 9,965 | 421 | 362 | 394 | 335 | 368 | 431 | 470 | 421 | 447 | 453 | 527 |
| IV Drug User (IDU) | 2,235 | 65 | 53 | 42 | 56 | 54 | 53 | 55 | 53 | 53 | 35 | 48 |
| MSM/IDU | 1,779 | 40 | 35 | 46 | 36 | 32 | 34 | 40 | 48 | 32 | 39 | 35 |
| Hemophiliac (Adult) | 82 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Heterosexual Contact | 1,479 | 60 | 64 | 68 | 79 | 99 | 70 | 77 | 80 | 64 | 63 | 51 |
| Transfusion/transplant (Adult) | 125 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No indicated risk (Adult) | 1,011 | 107 | 140 | 77 | 60 | 67 | 107 | 103 | 106 | 136 | 141 | 160 |
| Pediatric Hemophiliac | 17 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pediatric transfusion/transplant | * | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Mother HIV+ | 121 | * | * | * | 8 | * | * | * | * | * | * | 7 |
| Pediatric (no indicated risk) | 9 | 0 | 0 | 0 | 0 | * | * | * | 0 | * | 0 | 0 |
| Total | 16,830† | 700† | 660† | 630† | 570† | 628 | 700† | 750† | 710† | 740† | 740† | 828 |

Note: * Cell suppressed due to non-zero count less than 6; † Sum rounded to nearest tens unit due to non-zero addend less than 6; Due to reporting delays, all numbers are provisional (2018 volume as of 07/01/2019).

Source: Arizona Department of Health Services, Bureau of Epidemiology and Disease Control, Office of HIV/AIDS Services.